Michelle Leemans, Pierre Bauër, Vincent Cuzuel, Etienne Audureau, Isabelle Fromantin
{"title":"Volatile Organic Compounds Analysis as a Potential Novel Screening Tool for Breast Cancer: A Systematic Review.","authors":"Michelle Leemans, Pierre Bauër, Vincent Cuzuel, Etienne Audureau, Isabelle Fromantin","doi":"10.1177/11772719221100709","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>An early diagnosis is crucial in reducing mortality among people who have breast cancer (BC). There is a shortfall of characteristic early clinical symptoms in BC patients, highlighting the importance of investigating new methods for its early detection. A promising novel approach is the analysis of volatile organic compounds (VOCs) produced and emitted through the metabolism of cancer cells.</p><p><strong>Methods: </strong>The purpose of this systematic review is to outline the published research regarding BC-associated VOCs. For this, headspace analysis of VOCs was explored in patient-derived body fluids, animal model-derived fluids, and BC cell lines to identify BC-specific VOCs. A systematic search in PubMed and Web of Science databases was conducted according to the PRISMA guidelines.</p><p><strong>Results: </strong>Thirty-two studies met the criteria for inclusion in this review. Results highlight that VOC analysis can be promising as a potential novel screening tool. However, results of <i>in vivo</i>, <i>in vitro</i> and case-control studies have delivered inconsistent results leading to a lack of inter-matrix consensus between different VOC sampling methods.</p><p><strong>Discussion: </strong>Discrepant VOC results among BC studies have been obtained, highly due to methodological discrepancies. Therefore, methodological issues leading to disparities have been reviewed and recommendations have been made on the standardisation of VOC collection and analysis methods for BC screening, thereby improving future VOC clinical validation studies.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134002/pdf/","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11772719221100709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 13
Abstract
Introduction: An early diagnosis is crucial in reducing mortality among people who have breast cancer (BC). There is a shortfall of characteristic early clinical symptoms in BC patients, highlighting the importance of investigating new methods for its early detection. A promising novel approach is the analysis of volatile organic compounds (VOCs) produced and emitted through the metabolism of cancer cells.
Methods: The purpose of this systematic review is to outline the published research regarding BC-associated VOCs. For this, headspace analysis of VOCs was explored in patient-derived body fluids, animal model-derived fluids, and BC cell lines to identify BC-specific VOCs. A systematic search in PubMed and Web of Science databases was conducted according to the PRISMA guidelines.
Results: Thirty-two studies met the criteria for inclusion in this review. Results highlight that VOC analysis can be promising as a potential novel screening tool. However, results of in vivo, in vitro and case-control studies have delivered inconsistent results leading to a lack of inter-matrix consensus between different VOC sampling methods.
Discussion: Discrepant VOC results among BC studies have been obtained, highly due to methodological discrepancies. Therefore, methodological issues leading to disparities have been reviewed and recommendations have been made on the standardisation of VOC collection and analysis methods for BC screening, thereby improving future VOC clinical validation studies.
早期诊断对于降低乳腺癌(BC)患者的死亡率至关重要。BC患者缺乏特征性的早期临床症状,这突出了研究早期发现BC的新方法的重要性。一种很有前途的新方法是分析通过癌细胞代谢产生和排放的挥发性有机化合物(VOCs)。方法:本系统综述的目的是概述有关bc相关VOCs的已发表研究。为此,研究人员在患者体液、动物模型体液和BC细胞系中对VOCs进行了顶空分析,以识别BC特异性VOCs。根据PRISMA指南对PubMed和Web of Science数据库进行系统检索。结果:32项研究符合纳入本综述的标准。结果表明,挥发性有机化合物分析是一种有潜力的新型筛选工具。然而,体内、体外和病例对照研究的结果不一致,导致不同VOC取样方法之间缺乏基质间的共识。讨论:在BC研究中获得了不同的VOC结果,这很大程度上是由于方法上的差异。因此,本文回顾了导致差异的方法学问题,并对用于BC筛查的VOC收集和分析方法的标准化提出了建议,从而改进了未来VOC的临床验证研究。